Soft Tissue Sarcoma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The soft tissue sarcoma market size is expected to increase from USD 4.03 billion in 2025 to USD 4.38 billion in 2026 and reach USD 6.67 billion by 2031, growing at a CAGR of 8.75% over 2026-2031. This report is Segmented by Offering (Diagnosis, Treatment), Type of Sarcoma (Liposarcoma, Leiomyosarcoma, Synovial Sarcoma, Rhabdomyosarcoma, MPNST, Others), End User (Hospitals, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers, Others), and Geography (North America, Europe, Asia-Pacific, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Soft Tissue Sarcoma Market Trends and Insights

Rising Incidence of Soft Tissue Sarcoma and Earlier Referral to Specialty Centers

Cancer Research UK reported that soft tissue sarcoma incidence rates in England increased by 7% over the past decade, and the rise was tied to stronger surveillance and demographic aging rather than to a new exposure pattern. For the soft tissue sarcoma market, the more important effect is that earlier referral brings more patients into specialist pathways before care becomes delayed or fragmented. The 2025 GEIS guidelines set MRI as the first-line imaging modality and core needle biopsy with 3-4 cores at referral centers as the procedural standard, which formalizes the route into advanced diagnosis and treatment. Multidisciplinary tumor boards at regional sarcoma centers in Germany, France, and the United Kingdom are also making referral thresholds more consistent and shortening the path from suspicion to specialist consultation. This means the soft tissue sarcoma market gains not only from case capture, but also from higher procedure intensity per patient across imaging, biopsy, pathology review, and molecular testing.

Expansion of Targeted Therapy and Immunotherapy Pipelines

The August 2024 FDA accelerated approval of afamitresgene autoleucel for unresectable or metastatic synovial sarcoma established the first engineered T-cell receptor therapy approved for any solid tumor and reported a 43.2% overall response rate in the SPEARHEAD-1 Cohort 1 trial of 44 patients. The June 2026 full approval expanded the label to patients 12 years of age and older and reported a confirmed overall response rate of 43.8% across 137 patients, with 31.9% of responders maintaining durable response at 24 months. In the soft tissue sarcoma market, that change matters because revenue growth is being driven by premium therapies in biomarker-selected patients rather than by a broad increase in diagnosis alone. The soft tissue sarcoma market is also seeing deeper investment across PD-1 and PD-L1 programs, CDK4-directed approaches, antibody-drug conjugates, and next-generation TCR platforms, which supports a wider precision treatment mix over time. As more subtype-specific programs mature, commercial leadership in the soft tissue sarcoma market is likely to depend less on broad oncology scale and more on biomarker access, referral depth, and execution at qualified treatment sites.

Small Patient Pools and Trial Recruitment Bottlenecks Across Subtypes

Soft tissue sarcoma includes more than 70 histologic subtypes, and that fragmentation limits how much statistical power can be achieved in any single late-stage trial. In rare subtypes such as malignant peripheral nerve sheath tumor and alveolar soft part sarcoma, even modest studies can take years to enroll, which slows approval timing and keeps competitive entry narrow. For the soft tissue sarcoma market, that means the strongest commercial momentum still sits in subtypes large enough to support more conventional development paths, especially liposarcoma and leiomyosarcoma. Sponsors are trying to reduce this constraint by combining histologies in basket-style approaches and by seeking approval routes based on response endpoints rather than waiting for long survival readouts. Until subtype registries and biomarker-preselected cohorts become broader and more consistent, the soft tissue sarcoma market will continue to face slower launch cadence than larger oncology categories.

Other drivers and restraints analyzed in the detailed report include:

• Greater Use of MRI, Core Needle Biopsy, and Molecular Profiling in Diagnostic Workups
• Liquid Biopsy and ctDNA Adoption for Response Monitoring and Minimal Residual Disease Detection
• High Cost of Multimodal Treatment and Advanced Diagnostics

Segment Analysis

Treatment held 68.31% of the soft tissue sarcoma market share in the by offering category in 2025, and it is also the fastest-growing sub-segment with a 9.38% CAGR through 2031. The treatment side of the soft tissue sarcoma market is carrying the largest revenue base because systemic therapy, surgery, and combination regimens still anchor most care pathways across common and advanced disease settings. New biomarker-selected therapies are raising the ceiling of this segment because durable responses in specific subtypes support premium pricing and specialist delivery models. Even with this shift, chemotherapy still retains broad use because it remains the backbone for leiomyosarcoma and several other higher-volume soft tissue sarcoma settings.

Diagnosis represents the balance of the by offering structure, and its role in the soft tissue sarcoma market is becoming more strategic as therapy access increasingly depends on biomarker confirmation. Comprehensive genomic profiling, fusion detection, and MAGE-A4-linked testing are raising the value of pathology and laboratory services because they sit earlier in the treatment authorization path. MRI also remains central because it is the guideline-based first-line modality and because specialist centers are building more structured imaging capacity around sarcoma referrals. Other diagnostic methods, including liquid biopsy-based monitoring, are still mostly concentrated in academic use, but they are laying the groundwork for a recurring testing stream inside the soft tissue sarcoma market as validation improves.

Complete Report Scope:

• By Offering
  • Diagnosis
    • Biopsy
    • Imaging
    • Molecular Diagnostics
    • Other Diagnostic Methods
  • Treatment
    • Surgery
    • Radiation Therapy
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy
    • Other Treatments
• By Type of Sarcoma
  • Liposarcoma
  • Leiomyosarcoma
  • Synovial Sarcoma
  • Rhabdomyosarcoma
  • Malignant Peripheral Nerve Sheath Tumor (MPNST)
  • Other Types of Sarcoma
• By End User
  • Hospitals
  • Cancer Research Centers
  • Diagnostic Laboratories
  • Ambulatory Surgical Centers
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.61% of the soft tissue sarcoma market share in 2025, which made it the largest regional contributor by revenue. The region benefits from dense specialist center coverage, orphan drug frameworks that support faster rare cancer approvals, and reimbursement structures that can absorb higher-cost therapies more readily than many other regions. The United States drives most of that value because it combines referral depth, commercial drug uptake, and qualified treatment site infrastructure in a way that few other countries can match. Canada adds demand, but its public funding structure can produce a different access timeline for premium therapies. Europe held the second-largest position in the soft tissue sarcoma market, supported by reference networks that concentrate expertise and trial activity across France, Germany, Italy, Spain, and the United Kingdom.

Asia-Pacific is the fastest-growing region and is projected to expand at a 9.65% CAGR through 2031 in the soft tissue sarcoma market. Growth is being supported by rising molecular diagnostics capacity, stronger oncology investment, and rare cancer regulatory actions that can accelerate access in selected countries. Japan stands out because the Ministry of Health, Labour and Welfare approved atezolizumab for unresectable alveolar soft part sarcoma in February 2025, making it the first approved immune checkpoint inhibitor for that ultra-rare indication. China remains a large long-term opportunity in the soft tissue sarcoma market, but standardized post-operative management and molecular profiling are still more uneven outside major urban centers.

South Korea and India are emerging as the next important growth engines in Asia-Pacific because each supports a different part of the expansion path for the soft tissue sarcoma market. South Korea contributes through a strong diagnostics environment, while India is building relevance through rising oncology research investment and broader trial participation. South America and the Middle East and Africa remain earlier-stage parts of the soft tissue sarcoma market because specialist centers, reimbursement depth, and molecular pathology access are still limited outside major cities. Brazil and Argentina have the largest patient pools in South America, while GCC countries are adding cancer center capacity that should gradually widen addressable demand over time.

List of Companies Covered in this Report:

• Adaptimmune Therapeutics plc
• AstraZeneca
• Bayer
• Bristol-Myers Squibb
• Daiichi Sankyo
• Eisai
• Eli Lilly and Company
• Roche
• GlaxoSmithKline
• Illumina
• Merck
• Nanobiotix S.A.
• Novartis
• Pfizer
• QIAGEN
• Sanofi
• Sun Pharmaceuticals Industries
• Teva Pharmaceutical Industries
• Thermo Fisher Scientific
• Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support